Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics

Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumors
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news